Substantial doubt about the company's ability to continue as a going concern.
“The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The Company has accumulated deficit from inception (January 31, 2022) to February 28, 2026, of $288,623. These factors among others raise substantial doubt about the ability of the company to continue as a going concern for a reasonable period of time.”View the 10-Q filed Jun 16, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LMMY
this stock
Exousia Bio, Inc.
|
$635,250 | -96.1% | -67.4% | — | 0.0% |
|
EDU
New Oriental Education & Technology Group Inc.
|
$8.14B | -4.6% | +15.5% | — | 0.1% |
|
TAL
TAL Education Group
|
$5.52B | -8.8% | +33.7% | — | 3.7% |
|
LAUR
Laureate Education, Inc.
|
$4.74B | +3.8% | +19.5% | 12.9 | 2.4% |
|
CVSA
Covista Inc.
|
$3.96B | +15.0% | +9.3% | 16.3 | 8.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LMMY | -30.9% | -41.3% | -96.0% | -10.4% | -96.1% |
| SPY | -0.9% | -1.3% | +2.3% | +0.5% | +11.4% |
| vs SPY | -30.0% | -40.0% | -98.3% | -10.9% | -107.6% |
